HOYA Corp.

HOYA Corp., a key player in the Pharmaceuticals & Biotechnology sector, saw a decline on April 17, 2026, amid a broader market downturn. However, the company has demonstrated strong performance over the past year, with significant net profit growth and solid financial fundamentals, indicating resilience and long-term potential.

HOYA Corp. has experienced notable market activity, achieving an intraday high amid a rising Japan Nikkei 225 index. Over the past year, the company has significantly outperformed the index, showcasing strong fundamentals, including a high Return on Equity and impressive net profit growth, alongside robust operational cash flow.

HOYA Corp., a major player in the Pharmaceuticals & Biotechnology sector, has shown notable performance, gaining 3.56% today and achieving an intraday high. The company has demonstrated resilience with a 2.01% weekly gain and a 19.21% year-to-date increase, alongside impressive long-term returns and strong financial metrics.

HOYA Corp., a key player in the Pharmaceuticals & Biotechnology sector, faced a significant stock price decline today. Despite this, the company has shown strong performance over the past year, with a notable increase and solid financial metrics, including a low debt-to-equity ratio and robust return on equity.

HOYA Corp., a key player in the Pharmaceuticals & Biotechnology sector, saw a decline on March 4, 2026, amid a broader market downturn. Despite recent losses, the company has shown strong annual growth and maintains solid financial health, highlighted by a robust return on equity and low debt levels.

HOYA Corp., a key player in the Pharmaceuticals & Biotechnology sector, faced a decline on February 27, 2026, despite showing resilience in its performance metrics. The company has achieved significant returns over various periods and maintains a strong financial position, indicating its growth potential in a competitive market.

HOYA Corp. has seen a notable rise in stock performance, contrasting with a decline in the Japan Nikkei 225. The company has shown solid growth over various timeframes, with impressive returns and strong financial metrics, including a high Return on Equity and a low debt-to-equity ratio, reflecting its robust market position.

HOYA Corp. has experienced notable gains today, reaching an intraday high and showing a strong weekly and monthly performance compared to the Japan Nikkei 225. The company maintains solid financial health with a high return on equity and consistent positive results, although its annual performance has lagged behind the market.

HOYA Corp., a key player in the Pharmaceuticals & Biotechnology sector, has seen significant gains recently, outperforming the Japan Nikkei 225. The company boasts a solid financial foundation, with a strong Return on Equity and consistent positive results over the past five quarters, indicating robust operational performance.

HOYA Corp., a key player in the Pharmaceuticals & Biotechnology sector, saw its stock decline significantly on October 14, 2025. Despite recent challenges, the company maintains strong long-term fundamentals, including a solid return on equity and consistent positive results over the past five quarters, while navigating a competitive market.

HOYA Corp., a key player in the Pharmaceuticals & Biotechnology sector, has shown significant growth recently, outperforming the Japan Nikkei 225 in both weekly and monthly performance. The company maintains strong financial health with a solid return on equity and consistent positive results over the last five quarters.

HOYA Corp. has seen a notable increase in stock performance, rising significantly today and demonstrating strong weekly and monthly gains. Despite underperforming over the past year compared to the market, the company maintains solid financial fundamentals, including a high Return on Equity and a strong operating profit margin.